Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Takahashi, Shunji; Karayama, Masato; Takahashi, Masato; Watanabe, Junichiro; Minami, Hironobu; Yamamoto, Noboru; Kinoshita, Ichiro; Lin, Chia‐Chi; Im, Young‐Hyuck; Achiwa, Issei; Kamiyama, Emi; Okuda, Yasuyuki; Lee, Caleb; Bang, Yung‐Jue

doi:10.1158/1078-0432.ccr-21-1560

Public

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Published in Clinical Cancer Research • Aug 23, 2021

Authors:

Shunji Takahashi

Masato Karayama

Masato Takahashi

Abstract

Abstract Purpose: To evaluate drug–drug interactions between the human epidermal growth factor receptor 2 (HER2)–targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole. Patients and Methods: Patien...

Subject

Cmax

Medicine

Cohort

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!